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Abstract
Background: Parkinson’s disease (PD) is a neurodegenerative disorder resulting in
motor disturbances that can impact normal gait. Although PD initially responds well
to pharmacological treatment, as the disease progresses efficacy often fluctuates over
the course of the day, and clinical management would benefit from long-term
objective measures of gait. We have previously described a small device worn on the
shank that uses acceleration and angular velocity sensors to calculate stride length
and identify freezing of gait in PD patients. In this study we extend validation of the
gait monitor to 24-h using simultaneous video observation of PD patients.
Methods: A sleep laboratory was adapted to perform 24-hr video monitoring of
patients while wearing the device. Continuous video monitoring of a sleep lab,
hallway, kitchen and conference room was performed using a 4-camera security
system and recorded to hard disk. Subjects (3) wore the gait monitor on the left
shank (just above the ankle) for a 24-h period beginning around 5 pm in the
evening. Accuracy of stride length measures were assessed at the beginning and
end of the 24-h epoch. Two independent observers rated the video logs to identify
when subjects were walking or lying down.
Results: The mean error in stride length at the start of recording was 0.05 m (SD 0)
and at the conclusion of the 24 h epoch was 0.06 m (SD 0.026). There was full
agreement between observer coding of the video logs and the output from the gait
monitor software; that is, for every video observation of the subject walking there
was a corresponding pulse in the monitor data that indicated gait.
Conclusions: The accuracy of ambulatory stride length measurement was
maintained over the 24-h period, and there was 100% agreement between the
autonomous detection of locomotion by the gait monitor and video observation.
Keywords: accelerometry, stride length, motor fluctuations, levodopa, Parkinsonian
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder that results from a progressive
loss of dopaminergic neurons, predominantly within the substantia nigra. One of the
disabling clinical manifestations of PD is locomotor dysfunction; shortened stride length,
increased variability of stride, reduced walking speed, and freezing of gait (a transient
block of movement, particularly when initiating gait, turning, or negotiating an obstacle).
Treatment of PD to a large extent focuses on replacing depleted dopamine at the
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any medium, provided the original work is properly cited.striatum to improve locomotor function and maintain mobility for as long as possible
[1]. While dopamine replacement therapy (most commonly with the dopamine precur-
sor levodopa) is initially effective, most patients develop motor fluctuations after 3 years
of treatment [2]. ‘On’ states, in which the motor symptoms of PD are effectively treated,
may become shorter (’wearing off’), and periods of stiffness and difficulty of movement
(’off’ states) may occur unpredictably and more frequently [3].
Evaluation of long term medication response in PD usually takes the form of a
patient diary, where the Parkinsonian state is noted as ‘on’, ‘off’ or ‘on with dyskinesias
(levodopa-induced involuntary movements)’ [4,5], but these subjective records can be
unreliable [6]. The Unified Parkinson’s Disease Rating Scale (UPDRS) [7] is commonly
used in research studies (and to a lesser extent in the clinic) to intermittently assess
PD symptoms. Despite widespread acceptance (70% of PD clinical trials utilized the
UPDRS from 1994-1998 [8]) it is a relatively blunt instrument; analysis of gait is lim-
ited to assigning a single value between 0 (normal) and 4 (unable to walk, even with
assistance) from brief clinical observation. Motor function in PD patients can fluctuate
markedly over the course of a day, and an objective long-term measure of gait may
provide more effective titration of dopaminergic medication, better comparative treat-
ment evaluations, and possibly a more accurate diagnosis of PD when administering
the levodopa challenge test [9].
Wrist [10,11] and belt [12] mounted accelerometers have been used for long-term
monitoring of gross motor function in PD, but this approach is unable to determine
‘off’ from ‘on’ states. A more ‘brute force’ approach (six tri-axial accelerometers;
mounted on both upper arms, both upper legs, the sternum and one wrist) has been
used to distinguish between ‘on’ and ‘off’ stages in PD [13], but the complexity of
multi-segment accelerometry limits long-term use in the community. We have pre-
viously described a device for ambulatory assessment of gait using an array of linear
and angular sensors (multi-axis accelerometer and gyroscope) placed on the lateral
shank just above the ankle [14], which determines the length of every stride taken. In
Parkinson’s patients, the gait monitor has demonstrated sensitivity to motor fluctua-
tions (rapid changes in stride length) following levodopa administration over short
epochs (up to 3 h) [15,16] and can reliably detect episodes of freezing of gait from the
frequency characteristics of vertical leg acceleration [17]. As motor fluctuations in PD
occur over the entire day, the aim of the current study was to validate ambulatory
monitoring of gait in PD patients over a 24-h epoch by a direct comparison with
simultaneous video observation.
2. Methods
2.1 Participants
This study was approved by the Institutional Review Boards at Mount Sinai School of
Medicine and IM Systems Inc. (Baltimore, MD); informed written consent was
obtained from all participants. Stride length measures from the gait monitor were vali-
dated while walking along a 30-m hallway in healthy control subjects (N = 9; 5 males
and 4 females; mean age 55 years (SD 2)), and PD patients (Table 1) prescribed oral
levodopa (N = 4; 3 female and 1 male; 71 years (SD 6.4)). Three of these PD patients
(2 female and 1 male; 73 years (SD 6.4)) participated in 24-h assessments of the gait
monitor in a sleep laboratory, and during activities of daily living in the community.
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A prototype gait monitor was developed by IM Systems based on a design described pre-
viously [14]. The sensor array consisted of a dual axis gyroscope (InvenSense IDG-300)
and triaxial accelerometer (Freescale Semiconductor MMA7260QT). A 12 bit A/D con-
verter sampled linear and angular leg movement at a rate of 100 Hz and saved the digital
data on an SD flash memory card. An onboard 8-bit microcontroller was programmed
to communicate with the PC software and, in conjunction with a real time clock, man-
age the start and stop of the data logging. This allowed the implementation of advanced
features such as delayed recording, and accurate start and stop timing. The entire device,
including a rechargeable lithium ion battery, was housed in a plastic enclosure (66 mm ×
80 mm × 28 mm) and weighed 130 grams. Locomotor activity was identified by the
appearance of power in the vertical acceleration trace in a narrow band centered on 2
Hz [18]; periods when the subject was lying down were determined from the change in
baseline vertical acceleration from 9.8 m/s
2 to close to zero. Stride length was calculated
from vertical acceleration and pitch angular velocity of the leg [14].
2.3 Stride length accuracy
Subjects (9 controls and 4 PD patients) were fitted with a chalk ‘spur’ attached to the rear
of the left shoe, and asked to walk along a 30-m hallway while varying the length of their
steps. The gait monitor was also worn on the left leg. After testing, the length of each
stride was determined by measurement of the distance between successive chalk marks on
the floor, and compared to the stride length determined by the gait monitor [14].
2.4 24-h ambulatory gait monitoring
The sleep laboratory at IM Systems was adapted to perform 24-hr video monitoring of PD
patients while wearing the gait monitor. The sleep lab is a one-bed research facility with an
armchair, TV and DVD player. Restroom/shower and kitchen facilities were adjacent. In
addition, a 30-m hallway and conference room were available for patient use. Continuous
video monitoring of the sleep lab, hallway, kitchen and conference room was performed
using an integrated security system (VSS40DM 4-Camera DVR System, Supercircuits Inc,
TX) and recorded to hard disk. The three PD patients participating in the 24-h study arrived
at IM Systems in the early evening (around 5:00 pm). Following instrumentation, the 24 h
period began with an accuracy validation along the 30-m hallway (see section 2.3 above),
with the subject wearing the chalk ‘spur’ to allow a comparison between actual and mea-
sured stride length. Subjects stayed within IM Systems’ premises over the 24-h epoch, and
performed a final accuracy test prior to ending participation in the study the next evening.
Two independent observers (who were not privy to the gait monitor data) viewed the
24-h digital video records of the 3 PD subjects and independently coded gait activity
Table 1 Patient Characteristics
Subject ID Gender Age (yr) Disease Duration (yr) Levodopa Dose Equivalency (mg)
006 F 66 12 600
007* F 77 2 750
011* M 76 6 700
012* F 65 12 665
Characteristics of the four Parkinson’s disease patients at the time of the study. All four subjects performed the stride
length validation. Three patients (denoted by ‘*’ adjacent to subject ID) participated in the 24-h video validation.
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lution of 1 s. If the subject walked into an area outside of the view of the surveillance
cameras (the restroom or other blind spots), or walked into view from an unmonitored
area, the gait activity was coded as a partial observation. After coding, the results from
the two observers were compared and found to be almost identical; any instances of
disagreement (a missed episode of locomotion, for example) were reconciled by both
observers reviewing the period of video in question. The leg movement data from the
gait monitor was processed to determine stride length and the onset and cessation of
locomotor activity [14], and was synchronized with the video observation data (within
1 s) by alignment of the point at which the logger was activated by a button press
(captured on video). In addition, the three PD patients wore the gait device for 24-h
during normal daily activities in the community. Participants were requested to main-
tain a log of activities and when Parkinson’s-related medications were taken.
Results and Discussion
Mean stride length error while walking along a 30-m hallway was 0.064 m (SD 0.013;
range 0.03-0.08 m) for the control group (N = 9) and 0.045 m (SD 0.024; range 0.02-
0.07 m) for the four PD patients (Figure 1). Stride length accuracy was maintained
over the 24-h recording epoch (Figure 2); the mean error at the start of recording in
the subset of PD patients (N = 3) participating in this part of the study was 0.05 m
(SD 0, range 0.05-0.05 m) and at the conclusion of the 24-h period was 0.06 m (SD
0.026; range 0.03-0.08 m). There was 100% agreement between identification of loco-
motor activity and lying down by the gait monitor and from video observation for all 3
PD subjects. For every period of walking noted by the device there was an accompany-
ing period of locomotion coded in the video observations (Figure 3). This also held
true for identification of when the subject was lying down.
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Figure 1 Comparison of actual stride length (blue squares) and calculated stride length from the
gait monitor (red circles) from a healthy control (upper left plot) and a PD subject (lower left plot).
Subjects walked along a 30 m hallway wearing a chalk ‘spur’ to indicate heel strike. Scatter plots on the
right hand side demonstrate the linear relationship between actual and measured stride length.
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Figure 2 Stride length from a PD patient while walking along a 30-m hallway as determined by
chalk markings on the floor (blue squares) and the gait monitor (red circles). The top trace was
acquired at the start of testing and the lower trace was acquired following 24-h of continuous gait
monitoring. Accuracy in stride length measurement was maintained while wearing the gait monitor over
the 24-h epoch.
3 hours
Gait Monitor
Video Observation
walking
walking (partial observation)
lying down
Figure 3 Comparison of detection of locomotion and lying down in a PD patient by the gait
monitor (top plot) and from video observation (lower plot) over 24 h. A solid bar indicates that the
subject was walking as determined by the gait monitor (upper plot) or video observation (lower plot). A
partial observation (dashed line-lower trace only) indicates that the subject was out of view for a portion
of the gait event. Shaded regions indicate periods when the subject was lying down. There was full
agreement between the gait monitor results and independent video observation.
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an entire day of community living (Figure 4), keeping a simple written log of activities.
No subjects reported any discomfort or interference with activities of daily living or
sleep. A comparison of data from two PD patients over 24-h provides an indication of
the potential application of the gait monit o r( F i g u r e5 ) .P Dp a t i e n t1( F i g u r e5 A )w a s
recently diagnosed (2 years ago) at the age of 75 years, whereas PD patient 2 (Figure
5B) was diagnosed relatively young (53 years) with a disease duration of 12 years. Both
patients self-administered levodopa 5 times during the 24-h epoch (Figure 5A, B;
arrows), but it is clear that PD patient 1 (Figure 5A) exhibited a more consistent stride
length over the measurement period than patient 2.
The results of this study demonstrate the viability of ambulatory gait monitoring
using an integrated sensor array/data logger placed on the lateral shank over periods
of up to 24-h. Stride length accuracy was maintained over 24-h of continuous gait
monitoring and there was full agreement between autonomous detection of locomotion
(and periods of lying down) and video observation. Participants reported no discomfort
or inconvenience wearing the device for extended periods, whether in the laboratory or
during community activities. Data from 24-h community monitoring showed differ-
ences in motor fluctuations consistent with patient history; stride length was consistent
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Figure 4 Ambulatory gait monitoring over 24-h of activities of daily living. (A) Stride length data
(blue squares) and periods of lying down (shaded boxes) determined by the gait monitor over 24-h of
community living in a subject with PD. The activities were reported by the subject in a simple diary. The
vertical arrows indicate when PD related medications were self-administered. (B) Detail of 10-min of stride
length while shopping.
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Page 6 of 8over the day in a patient with late onset, short duration PD, whereas a patient with a
younger onset and longer duration exhibited considerable fluctuations in stride length
that appeared temporally linked to levodopa administration.
Conclusions
The accuracy of ambulatory stride length measurement in PD patients was maintained
over a period of 24-h. There was 100% agreement between the autonomous detection
of locomotion and periods of lying down from shank-mounted accelerometer output
and video observation by two independent raters. Long-term monitoring of gait in PD
provides an objective dynamic assessment of motor fluctuations and may prove a use-
ful adjunct in the management of Parkinson’s disease and other movement disorders
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Figure 5 Stride length data (blue squares) and periods of lying down (shaded boxes) during 24-h
ambulatory activity in the community. Comparison between the patient shown in Figure 4 (A) with a
late onset and short disease duration (2 years), exhibiting a consistent stride length over the day, with (B) a
PD patient with a longer disease duration (12 years) and relatively early onset (53 years). Note the
fluctuations in stride length over the 24-h epoch in the latter patient.
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